

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass

Respiratory Infection In Pediatrics

Renee Freeman
Laurie Streitenberger
Marion Yetman
Anne Augustin

Members of the Pediatric Interest Group of CHICA-Canada

Hosted by Paul Webber
paul@webbertraining.com

www.webbertraining.com



Agenda

- Viral Respiratory Infections
 - Transmission and Placement
- RSV
- Prevention of pneumonia - Neonatal ICU

Viral Respiratory Infections: Transmission and Placement

Laurie Streitenberger RN, BSc, CIC
Infection Control Practitioner

Outline

- Mode of Transmission
- PPE required
- Patient Placement

Mode of Transmission

Droplet

- large droplets (> 5 microns in diameter)
- released during coughing, sneezing, speaking, crying or during procedures such as suctioning or bronchoscopy
- propelled short distances (< 1 m)

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass

Mode of Transmission

Contact

- once expelled, organisms can settle on objects in the person's immediate environment (< 1m) and can be transmitted by unwashed hands to other individuals

Droplet Precautions

Initiated when:

- patients have symptoms of droplet transmitted infections and/or;
- patients have laboratory confirmed droplet transmitted infections

Personal Protective Equipment (PPE)

Donning of PPE

- Hand Hygiene
- Gown
- Fluid resistant procedure mask with eye protection (or mask and then visor/goggles)
- Gloves

Personal Protective Equipment (PPE)

Removal of PPE

- Gloves
- Gown
- Hand hygiene
- Fluid resistant procedure mask with eye protection (or visor/goggles and then mask)
- Hand Hygiene

Patient Placement

Gold standard = private/single room 

Cohorting

- practice of grouping patients and staff with the same infection together in order to prevent transmission to other patients and staff
- usually considered when bed or staffing limitations necessitate consideration of alternatives other than the ideal, and often microbiological data are not available

Cohorting

Overriding principles:

- Patients are not infected with other potentially transmissible microbes, and
- It is unlikely that the patients will get reinfected by the same organism, and
- None of the patients are severely immunocompromised

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass

Other Considerations

- Staffing cohort issues
- Dedicated patient equipment
- PPE for family/visitors
- Visiting restrictions
- ?Discontinuing precautions

Respiratory Syncytial Virus

Marion Yetman RN, BN, MN, CIC
Infection Control Nurse Coordinator

Objectives

- Understand the disease process of RSV
 - Epidemiology
 - Pathophysiology
 - S/S
 - Risk Factors, Diagnosis
 - Prevention
 - ICP Role
 - Prophylaxis

Respiratory Syncytial Virus -(RSV)

- RNA Virus
- Identified in 1957
- Organ specific mainly affects the respiratory tract
- Syncytial

Epidemiology

- Seasonal epidemics
- Humans are only source of infection
- Infects all children by age 3
- Incubation period 4-6 days
- Viral shedding – usually 3-8 days
- Peak incidence is 2-6 months of age
- Re-infection may occur, but is less severe

Pathophysiology

- Diffuse airway obstruction in the small bronchi
- Airway swelling, sloughing of necrotic debris, loss of cilia
- Increased mucous production
 - Leads to partial obstruction- hyperinflation
 - complete obstruction- atelectasis

Controlling Pediatric Respiratory Infections


Laurie Streitenberger, Marion Yetman & Anne Augustin

A Webber Training Teleclass


Pathophysiology

- Anatomical features
 - Airway smaller than adults
 - Greater number of mucous glands
 - Fewer pores of Kohn

Incidence of RSV in NL
RSV Positive Cases 1999-2004, by Age



RSV Positive Cases, by Month 2005-2006



Upper Respiratory Tract Symptoms

- Cough
- Runny nose
- Wheeze
- Decreased feeding
- Breathing difficulties
- Irritable
- Fever (2-4 days)
- Listless

Lower Respiratory Tract Symptoms

- Increased coughing
- Dyspnea
- Increased respiratory rate
- Retraction of intercostal muscles
- Hypoxemia
- Cyanosis (rare)
- Apnea – premature babies

Risk Factors for Disease

- Male
- Age < 6 months
- Birth during the first half of the RSV season
- Crowded living quarters/Siblings
- Day Care
- Passive cigarette smoke exposure
- Lack of breast feeding

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass

High Risk Population

- History of prematurity/BPD
- Congenital heart disease
- Immunosuppressed

Transmission

- Direct or indirect contact with the respiratory secretions
- RSV lives on countertops/bedrails for 7 hours, hands/gloves – 1 hour.

Diagnosis

- Clinical symptoms
- N-P swab
- Chest x-ray
 - hyperinflation
 - peribronchial thickening
 - interstitial infiltration

Prevention – ICP Role

- Awareness Campaign
 - Early
 - Media
 - Prenatal Classes
 - Family Doctors/Obs Staff
 - Late
 - Case Room/OBS Unit
 - Neonatal Unit
 - Community Health

Prevention – ICP Role

- Key Messages
 - What is RSV/Transmission/Who is at risk?
 - Parental role in prevention
 - Improve Handwashing
 - Avoid second hand smoke
 - Promote breastfeeding
 - Avoid crowds
 - Focus on respiratory etiquette

RSV Prophylaxis

Palivizumab (Synagis)

- Monoclonal antibody
- Monthly IM injections during RSV season
- Cost - \$7,000 - \$9,000/per child
- Cost absorbed by Provincial Health Depts

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin

A Webber Training Teleclass

NACI Recommendations 2003

- Premature infants <32 weeks GA
 - Less than 6 months by RSV Season
- Children <24 months with CLD or significant heart disease
- Children 33 – 35 weeks in remote communities who are < 6 mon by RSV Season

NL Experience

- Initially as per NACI guidelines
- Regional re-hospitalization determines cost effectiveness
- Palvizumab discontinued in Health Infants
 - 29 –32 weeks

Retrospective Cohort Study

- Sample
 - All infants <32 weeks GA June 01, 1999 – December 31, 2004
 - Infants ‘High Risk’
 - CLD or CHD
 - Healthy Infants 29 –32 weeks

Outcome of “Healthy” Babies 29-32 weeks GA N=100

Indicator	Palvizumab YES	Palvizumab NO
Number of infants	28	72
Number RSV Deaths	0	0
Readmitted with respiratory disease	3	3
Number RSV [⊕]	0	0
Number ventilated With respiratory disease	0	0
Total Cost of RSV-RH	43,054	37,183

P=0.310

Cost of Prophylaxis versus Readmission for Respiratory Distress

Cost of Prophylaxis for 100 infants	\$700,000.00
Cost of Readmission For 6 Children	80,237
Cost Saving in 5 years	\$619,763.00

Conclusions

- Based on local evidence, it is reasonable and safe to withhold Palvizumab for healthy infants 29 – 32 weeks gestational age in NL
- Cost of the prophylaxis for “healthy infants” (29 -32 weeks GA) could be better utilized for Prevention

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin

A Webber Training Teleclass

Prevention of pneumonia - Neonatal ICU

Anne Augustin, MLT, CIC
Infection Prevention & Control Coordinator

Outline

- The Problem
- Risk Factors
- Prevention Recommendations

Pneumonia Prevention – NICU

- Clinical presentation
 - Difficult to diagnosis
 - Non-infectious processes may show same clinical presentation
 - Underlying lung conditions -> difficult to interpret
 - Culture from endotracheal tube may be helpful
 - Often colonized
 - Often treated empirically

CDC pneumonia definition < 1 year old

- Worsening gas exchange
- And at least 3 of the following
 - Temperature instability
 - Leukopenia or leukocytosis
 - New onset of purulent sputum, change in character, increased respiratory secretions, increased suctioning requirements
 - Apnea, tachypnea, nasal flaring with retraction of chest wall or grunting
 - Wheezing, rales or rhonchi
 - Cough
 - Bradycardia or tachycardia

Pneumonia Prevention – NICU

- Common causative agents
 - Early onset
 - Usually associated with intrapartum infection and early-onset sepsis
 - Group B Streptococcus
 - NNIS data from 1986 to 1994
 - *S. aureus* (18.7%)
 - Coag. Negative Staph (16.6%)
 - *Pseudomonas aeruginosa* (12.9%)
 - *Enterobacter* (9.5%)
 - Respiratory Viruses

Pneumonia Prevention – NICU

Birth Weight	NNIS 2001	NNIS 2004
< 1000 g	4.8	3.5
1001 – 1500 g	3.6	2.4
1501 – 2500 g	2.9	1.9
> 2500 g	2.6	1.4

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass

Pneumonia Prevention – NICU

- Risk Factors – innate
 - Immunocompromised
 - Decreased chemotaxis and phagocytosis by macrophages
 - Lack of or abnormal “normal flora”

Pneumonia Prevention – NICU

- Risk factors – device & care related
 - Nasogastric or orogastric feeding tubes
 - Endotracheal tube
 - Quickly colonized
 - Poor fitting -> secretions slide around
 - Decreased level of consciousness
 - Sedation and use of paralytics
 - Aspiration of organisms colonizing the stomach or oropharynx
 - Prior bloodstream infection for those infants that are on ventilator (hematogenous spread)

Recommendations for Prevention

- **No ill staff, parents, family members or visitors allowed in the NICU**
 - Respiratory viruses
 - vomiting & diarrhea
 - “funny” rash
- Influenza vaccine for all staff
 - consider developing vaccine program for parents & family members
- RSV prophylaxis

Recommendations for Prevention

- Hand Hygiene for All
 - point of care hand hygiene
 - parent & family education
 - no false nails, no rings or arm jewelry
 - category 1A



Recommendations for Prevention

- Cleaning, disinfection & sterilization of equipment
 - use sterile water for rinsing reusable semicritical items after chemical disinfection
 - category 1A
- Breathing circuits
 - do not routinely change
 - change when malfunctioning or visibly soiled
 - category 1A

Recommendations for Prevention

- Breathing-circuit-tubing condensate
 - periodically drain and discard condensate
 - do not allow condensate to drain toward patient (category 1B)
- Sterile water for humidifier fluids (category II)
- Change heat-moisture exchanger (HME) when it malfunctions or is visibly soiled (category II)

Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass

Recommendations for Prevention

- oxygen humidifier-tubing (for one patient)
 - change when malfunctions or becomes visibly soiled (category II)
- small-volume medication nebulizers – in-line and hand-held nebulizers
 - clean, disinfect, rinse with sterile water and dry between treatments
 - use only sterile fluids
 - category IB

Recommendations for Prevention

- Resuscitation bags
 - sterilize or high level disinfect between use on different patients (category 1B)
- Suctioning of respiratory tract
 - single use open – sterile catheter (category II)
 - multiuse closed- system
 - frequency of changing (unresolved)
 - only sterile fluids (category II)


Recommendations for Prevention

- Temperature Probes
 - high level disinfect (category 1B)
- Aspiration Prevention
 - before deflating cuff of ETT, ensure secretions are cleared from above the cuff (category II)
 - elevate at an angle of 30 – 45 degrees the head of the bed (category II)
 - routinely verify the placement of feeding tube (category 1B)



References

- APIC Text of Infection Control & Epidemiology 2nd ed., Chapters 22 & 39, January 2005
- Horan TC, Gaynes RP, Surveillance of nosocomial infections. In: Hospital Epidemiology and Infection Control, 3rd ed., Mayhall Cg, editor. Philadelphia: Lippincott Williams & Williams, 2004: 1659-1702.
- National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992 – June 2001, Issued August 2001, Am J Infect Control 2001;29:404-21
- National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992 – June 2004, Issued October 2004, Am J Infect Control 2004 32:470-85
- Guidelines for Preventing Health-Care-Associated Pneumonia, 2003, Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee



Controlling Pediatric Respiratory Infections

Laurie Streitenberger, Marion Yetman & Anne Augustin
A Webber Training Teleclass



The Next Few Teleclasses

- | | |
|-----------|---|
| June 29 | <i>Bloodborne Pathogen Control Across the Continuum of Care</i>
... with Sue Sebazco |
| July 18 | <i>Infection Surveillance in the UK</i>
... with Dr. Allan Johnson |
| July 27 | <i>Demal Absorption of Alcohol Disinfectants</i>
... with Dr. Axel Kramer |
| August 17 | <i>The Spectre of a Flu Pandemic – Is It Inevitable?</i>
... with Dr. Lance Jennings, New Zealand |

Free Teleclasses
in July and August

For the full teleclass schedule – www.webbertraining.com